TY - JOUR
T1 - Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications
AU - Squassina, Alessio
AU - Manchia, Mirko
AU - Pisanu, Claudia
AU - Ardau, Raffaella
AU - Arzedi, Carlo
AU - Bocchetta, Alberto
AU - Caria, Paola
AU - Cocco, Cristina
AU - Congiu, Donatella
AU - Cossu, Eleonora
AU - Dettori, Tinuccia
AU - Frau, Daniela Virginia
AU - Garzilli, Mario
AU - Manca, Elias
AU - Meloni, Anna
AU - Montis, Maria Antonietta
AU - Mura, Andrea
AU - Nieddu, Mariella
AU - Noli, Barbara
AU - Paribello, Pasquale
AU - Pinna, Federica
AU - Robledo, Renato
AU - Severino, Giovanni
AU - Sogos, Valeria
AU - Del Zompo, Maria
AU - Ferri, Gian Luca
AU - Chillotti, Caterina
AU - Vanni, Roberta
AU - Carpiniello, Bernardo
N1 - Funding Information:
This work was supported with a grant funded by Fondazione di Sardegna and Regione Sardegna, Call 2016, Project ID: F72F16003090002, granted to AS. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. The authors have nothing to declare. The authors declare no competing interests.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
PY - 2020/12
Y1 - 2020/12
N2 - Individuals with severe psychiatric disorders have a reduced life expectancy compared to the general population. At the biological level, patients with these disorders present features that suggest the involvement of accelerated aging, such as increased circulating inflammatory markers and shorter telomere length (TL). To date, the role of the interplay between inflammation and telomere dynamics in the pathophysiology of severe psychiatric disorders has been scarcely investigated. In this study we measured T-lymphocytes TL with quantitative fluorescent in situ hybridization (Q-FISH) and plasma levels of inflammatory markers in a cohort comprised of 40 patients with bipolar disorder (BD), 41 with schizophrenia (SZ), 37 with major depressive disorder (MDD), and 36 non-psychiatric controls (NPC). TL was shorter in SZ and in MDD compared to NPC, while it was longer in BD (model F6, 137 = 20.128, p = 8.73 × 10−17, effect of diagnosis, F3 = 31.870; p = 1.08 × 10−15). There was no effect of the different classes of psychotropic medications, while duration of treatment with mood stabilizers was associated with longer TL (Partial correlation controlled for age and BMI: correlation coefficient = 0.451; p = 0.001). Levels of high-sensitivity C-Reactive Protein (hsCRP) were higher in SZ compared to NPC (adjusted p = 0.027), and inversely correlated with TL in the whole sample (r = −0.180; p = 0.042). Compared to NPC, patients with treatment resistant (TR) SZ had shorter TL (p = 0.001), while patients with TR MDD had higher levels of tumor necrosis factor-α (TNFα) compared to NPC (p = 0.028) and to non-TR (p = 0.039). Comorbidity with cardio-metabolic disorders did not influence the observed differences in TL, hsCRP, and TNFα among the diagnostic groups. Our study suggests that patients with severe psychiatric disorders present reduced TL and increased inflammation.
AB - Individuals with severe psychiatric disorders have a reduced life expectancy compared to the general population. At the biological level, patients with these disorders present features that suggest the involvement of accelerated aging, such as increased circulating inflammatory markers and shorter telomere length (TL). To date, the role of the interplay between inflammation and telomere dynamics in the pathophysiology of severe psychiatric disorders has been scarcely investigated. In this study we measured T-lymphocytes TL with quantitative fluorescent in situ hybridization (Q-FISH) and plasma levels of inflammatory markers in a cohort comprised of 40 patients with bipolar disorder (BD), 41 with schizophrenia (SZ), 37 with major depressive disorder (MDD), and 36 non-psychiatric controls (NPC). TL was shorter in SZ and in MDD compared to NPC, while it was longer in BD (model F6, 137 = 20.128, p = 8.73 × 10−17, effect of diagnosis, F3 = 31.870; p = 1.08 × 10−15). There was no effect of the different classes of psychotropic medications, while duration of treatment with mood stabilizers was associated with longer TL (Partial correlation controlled for age and BMI: correlation coefficient = 0.451; p = 0.001). Levels of high-sensitivity C-Reactive Protein (hsCRP) were higher in SZ compared to NPC (adjusted p = 0.027), and inversely correlated with TL in the whole sample (r = −0.180; p = 0.042). Compared to NPC, patients with treatment resistant (TR) SZ had shorter TL (p = 0.001), while patients with TR MDD had higher levels of tumor necrosis factor-α (TNFα) compared to NPC (p = 0.028) and to non-TR (p = 0.039). Comorbidity with cardio-metabolic disorders did not influence the observed differences in TL, hsCRP, and TNFα among the diagnostic groups. Our study suggests that patients with severe psychiatric disorders present reduced TL and increased inflammation.
UR - http://www.scopus.com/inward/record.url?scp=85090951874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090951874&partnerID=8YFLogxK
U2 - 10.1038/s41386-020-00844-z
DO - 10.1038/s41386-020-00844-z
M3 - Article
C2 - 32919410
AN - SCOPUS:85090951874
SN - 0893-133X
VL - 45
SP - 2229
EP - 2238
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 13
ER -